title: Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.
abstract: BACKGROUND
  Psoriatic arthritis often affects patients with psoriasis.
  
  
  OBJECTIVE
  To examine the effect of adalimumab on psoriatic arthritis in patients with moderate to severe psoriasis.
  
  
  METHODS
  Data from patients with psoriasis and a reported history of comorbid psoriatic arthritis in 3 randomized, placebo-controlled psoriasis trials of adalimumab were analyzed.
  
  
  RESULTS
  Adalimumab (n = 274) reduced the risk of psoriatic arthropathy adverse events by 75% versus placebo (1.1 vs. 4.8%; p = 0.025). Psoriasis/psoriatic arthritis-related pain was significantly reduced (-31.3 vs. -5.6 visual analog scale units; p < 0.0001). At week 16, adalimumab-treated patients were more likely to respond (56.9 vs. 4.5%; p < 0.001) and responded for a greater percentage of follow-up time (39.3 vs. 2.9%; p< 0.0001) than placebo-treated patients (regression model for PASI 75 and ACR 20 responses).
  
  
  CONCLUSIONS
  Adalimumab treatment of moderate to severe psoriasis reduced symptoms of comorbid psoriatic arthritis.
authors: Seattle Rheumatology Associates, Seattle, WA 98104, USA. pmease @ nwlink.com
authors: Philip J
authors: PJ
authors: Mease
authors: James
authors: J
authors: Signorovitch
authors: Andrew P
authors: AP
authors: Yu
authors: Eric Q
authors: EQ
authors: Wu
authors: Shiraz R
authors: SR
authors: Gupta
authors: Yanjun
authors: Y
authors: Bao
authors: Parvez M
authors: PM
authors: Mulani
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000191:economics; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab